Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BCDIN3D | Q7Z5W3 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876131 | 0.88 | PDE9A (0.34) | PDE10A | |
| SCHEMBL25875917 | 0.88 | PDE2A (0.40) | PDE2APDE4BSMN1; SMN2RAB9ABCDIN3D | |
| SCHEMBL25876275 | 0.87 | PDE1A (0.36) | PDE10APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25876233 | 0.87 | MAT2A (0.33) | PDE2APDE10APDE4APDE4BPDE4C | |
| SCHEMBL25875942 | 0.87 | MAT2A (0.42) | PDE4B | |
| SCHEMBL25876041 | 0.86 | MAT2A (0.35) | PDE2APDE10APDE4APDE4BPDE4C | |
| SCHEMBL25876077 | 0.85 | MERTK (0.35) | PDE10APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25876051 | 0.84 | PDE9A (0.35) | PDE10A | |
| SCHEMBL25875993 | 0.83 | MAT2A (0.33) | PDE2APDE10APDE4APDE4BPDE4C | |
| SCHEMBL25876330 | 0.83 | PDE4A (0.31) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PDE2A 1000/4885PDE10A 526/4885PDE4A 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.